Peptide research profile

TB-500

Also known as Ac-LKKTETQ · Thymosin beta-4 fragment

A synthetic N-acetylated fragment associated with thymosin beta-4. Direct TB-500 evidence is sparse; much of the frequently cited repair literature studied full-length thymosin beta-4 instead.

  • Repair & regeneration
  • Skin & connective tissue
Preclinical-heavy2 referencesEducational use

Dosing literacy

Dosing & scaling, explained

The 1–2 mg entries summarize source-library conventions; they are not supported by a validated human TB-500 dosing program. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Starting pointNot clinically established
    No validated titration window

    There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.

  2. Recorded preset1–2 mg per administration
    Calculator library reference

    This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.

  3. Higher exposureAbove 2 mg is not characterized
    Risk and uncertainty increase

    Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.

Drug amount and device markings are different quantities. The calculator converts mass into volume, syringe units, or pen clicks.

Schedule literacy

Patterns described in source material

  • Every 3 days to twice monthly in presets

    The cadence represented by the recorded calculator presets.

  • Full-length Tβ4 studies use different formulations

    Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.

  • No universal schedule

    No single schedule has been validated across products or research contexts.

Clinical context

No randomized human dose-ranging trial establishes systemic TB-500 exposure, schedule, or long-term safety.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Fragment metabolism

    Recent analytical work identifies TB-500 metabolites in serum systems and rats.

  • 02

    Cell migration

    In-vitro wound assays examine the parent fragment and selected metabolites.

  • 03

    Thymosin beta-4 repair biology

    Full-length Tβ4 literature covers wound, corneal, vascular, and cardiac models.

  • 04

    Anti-doping detection

    Analytical methods focus on parent peptide and urinary metabolites.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • In vitro

    Direct fragment assay

    A 2024 study compared TB-500 and metabolites in fibroblast wound-healing assays.

  • Animal

    Rat metabolism work

    The same study characterized metabolites after administration in rats.

  • Review

    Evidence is often conflated

    Findings for 43-amino-acid thymosin beta-4 cannot be assigned automatically to the seven-residue TB-500 fragment.

Recorded protocol library

Amounts recorded for TB-500

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Standard Dose Range · lower endpoint

    300 mcg

    Sign in for schedule, duration and source context.

  • 02

    Lower maintenance record

    1 mg

    Sign in for schedule, duration and source context.

  • 03

    Recorded cycle

    1.5 mg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Synthetic thymosin beta-4 fragment
Sequence
Ac-LKKTETQ
Amino acids
7
Approx. MW
889 Da
Origin / design
N-acetylated LKKTETQ actin-binding region

Important limitations

  • Direct human efficacy trials of TB-500 are not established.
  • Full-length thymosin beta-4 and TB-500 are chemically and evidentially distinct.
  • Sport anti-doping rules may prohibit thymosin-beta-4–related substances.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

2 curated references

  1. Simultaneous quantification of TB-500 and its metabolites and screening by wound-healing activitiesJournal of Pharmaceutical and Biomedical Analysis · 2024 · Animal
  2. Thymosin beta 4 accelerates wound healingJournal of Investigative Dermatology · 1999 · Animal

Related profiles